Adhera Therapeutics Stock Net Asset
ATRXDelisted Stock | USD 0.72 0.00 0.00% |
Adhera Therapeutics fundamentals help investors to digest information that contributes to Adhera Therapeutics' financial success or failures. It also enables traders to predict the movement of Adhera Pink Sheet. The fundamental analysis module provides a way to measure Adhera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adhera Therapeutics pink sheet.
Adhera |
Adhera Therapeutics Company Net Asset Analysis
Adhera Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Adhera Therapeutics Net Asset | 196 K |
Most of Adhera Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adhera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Adhera Therapeutics has a Net Asset of 196 K. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Adhera Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adhera Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Adhera Therapeutics could also be used in its relative valuation, which is a method of valuing Adhera Therapeutics by comparing valuation metrics of similar companies.Adhera Therapeutics is currently under evaluation in net asset category among its peers.
Adhera Fundamentals
Return On Asset | -4.48 | ||||
Current Valuation | 10.55 M | ||||
Shares Outstanding | 3.16 M | ||||
Shares Owned By Insiders | 21.87 % | ||||
Number Of Shares Shorted | 2.05 K | ||||
Price To Earning | (125.83) X | ||||
Price To Sales | 8.23 X | ||||
Gross Profit | (157 K) | ||||
EBITDA | (4.92 M) | ||||
Net Income | (6.35 M) | ||||
Cash And Equivalents | 849 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 7.35 M | ||||
Debt To Equity | 56.30 % | ||||
Current Ratio | 0.05 X | ||||
Book Value Per Share | (6.90) X | ||||
Cash Flow From Operations | (665 K) | ||||
Short Ratio | 3.24 X | ||||
Earnings Per Share | (0.52) X | ||||
Number Of Employees | 12 | ||||
Beta | -0.14 | ||||
Market Capitalization | 2.18 M | ||||
Total Asset | 196 K | ||||
Retained Earnings | (42.43 M) | ||||
Working Capital | 16.49 M | ||||
Current Asset | 20.36 M | ||||
Current Liabilities | 3.88 M | ||||
Net Asset | 196 K |
About Adhera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adhera Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adhera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adhera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Adhera Pink Sheet
If you are still planning to invest in Adhera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adhera Therapeutics' history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |